Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This pilot study will evaluate the feasibility and preliminary effectiveness of an adapted version of the Function Focused Care intervention, delivered by telephone, for improving aging in place for older adults living in subsidized housing. The study will include participants with and without mild cognitive impairment or mild dementia and will examine whether the study outcomes differ by cognitive status. Findings from this study will provide new information about how to optimize function and physical activity among older adults with and without cognitive impairment living in subsidized housing.
Description: Self-reported ability to perform 8 ADLs and 7 IADLs (Range, 0-30; higher scores indicate more functional impairment)
Measure: Change in Precipitating Events Project (PEP) Functional Status Scale from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: Objective measure of lower extremity functioning in older adults (Range, 0-12; higher scores indicate worse lower extremity functioning) The measure will be collected only if in-person contact is possible during the COVID-19 outbreak.
Measure: Change in Short Physical Performance Battery score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: Measured using Fitbit
Measure: Change in average step counts from baseline to 2 months for immediate intervention sites; change from 2 to 4 months for waitlist control sites Time: Measured continuously from 0-4 monthsDescription: Measured using Fitbit (minutes spent in each of 4 levels of activity: sedentary; lightly active; fairly active; very active)
Measure: Change in time spent in differing levels of activity from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: 0-4 monthsDescription: Self-reported physical activity (Range, 0-793; higher scores indicate greater physical activity)
Measure: Change in Physical Activity Scale for the Elderly (PASE) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported measure (Range, 13-52; higher scores indicate better quality of life)
Measure: Change in Quality of Life in Alzheimer's Disease (QOL-AD) scale from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported measure of depressive symptoms (Range, 0-27; higher scores indicate worse depressive symptoms)
Measure: Change in Patient Health Questionnaire (PHQ-9) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: 14-item self-reported scale (Range, 14-98; higher scores indicate higher levels of resilience)
Measure: Change in Resilience Scale (RS-14) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported hospitalization
Measure: Percentage of participants with a hospitalization during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites) Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported number of hospitalizations
Measure: Number of hospitalizations during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites) Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported emergency department visit
Measure: Percentage of participants with an emergency department visit during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites) Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported number of emergency department visits
Measure: Number of emergency department visits during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites) Time: Baseline, 2 months, 4 months for wait-list controlDescription: Self-reported or emergency contact-reported move to a higher level of care, defined as a move to assisted living, board and care, or nursing home
Measure: Percentage of participants with a move to a higher level of care (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites) Time: Baseline, 2 months, 4 months for wait-list controlDescription: Assessed using participant responses to invitation to participate in the study (enrolled vs. refused)
Measure: Feasibility of study recruitment, measured as percentage of eligible participants recruited Time: 0-4 monthsDescription: Assessed as percentage of participants who remain enrolled in the study
Measure: Feasibility of study retention, measured as percentage of participants retained over study follow-up Time: 0-4 monthsDescription: Fidelity checklist including each component, with fidelity measured as the percentage of total study protocol tasks completed (Range, 0-100%; higher percentage indicates higher fidelity)
Measure: Percentage fidelity to treatment protocol, measured using fidelity checklist Time: 0-4 monthsDescription: Assessed by psychologist (4 global scores, scored on a 5-point Likert scale from 1 (low) to 5 (high))
Measure: Fidelity to motivational interviewing, measured using the Motivational Interviewing Treatment Integrity Scale (MITI 4) Time: 0-4 monthsDescription: Self-reported acceptability of the intervention (5-point Likert scale ranging from very unacceptable (1) to very acceptable (5); higher numbers indicate higher acceptability)
Measure: Acceptability assessed using a survey question Time: 0-4 monthsDescription: Self-reported acceptability of the intervention assessed using open-ended questions (e.g., "How did the program fit into your life?"; no pre-specified range as responses are qualitative; more positive responses indicate higher acceptability)
Measure: Acceptability assessed using qualitative interviews Time: 0-4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports